First AD

Second AD

Dr Voss Application of Updated KEYNOTE-564 Data

Please briefly mention the recent retrospective findings with cabo post-len + pembro – (

Haro-Silerio, et al. ASCO GU 2024. Abstract 433

) = How do you approach treatment post-IO?

Please highlight recent data from the LITESPARK-011 trial(NCT04586231) evaluating belzutifan + lenvatinib vs cabozantinib in advanced RCC after anti-PD-L1 therapy (

      a.  Please also briefly mention the significance of recent data from the phase 3 LITESPARK-005 trial (NCT04195750) assessing belzutifan versus everolimus in previously treated advanced RCC patients

Albiges, et al. ESMO 2023. Abstract LBA88

       ii. Patient reported outcomes – (

Powles, et al. ASCO GU 2024. Abstract 361

      b.How does belzutifan fit into your treatment paradigm?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition